Guillermo Roa Álvarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guillermo Roa Álvarez has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Sergio Enrique Leal Osuna
4 shared publications- Mario Shuchleib Cukiert
Department of Dermatology Hospital General “Dr. Manuel Gea González” Mexico City Mexico
3 shared publications - Carlos Alberto Aguilar Salinas
Dirección de Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Ciudad de México, México...
2 shared publications - Ivette Cruz-Bautista
Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico
2 shared publications - Liliana Muñoz-Hernandez
Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , Vasco de Quiroga 15, Tlalpan, Mexico City 14080
2 shared publications - Adrian Soto-Mota
Metabolic Diseases Research Unit, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
1 shared publication
Latest Publications
- 1 October 2026
- Published by Medipiel Servicios Administrativos in Dermatología Cosmética, Médica y Quirúrgica
- Vol. 24 (3) , 420-430
Síndrome de hipersensibilidad a medicamentos: revisión de la literatura con énfasis en los criterios diagnósticos
El síndrome de hipersensibilidad a medicamentos (DHS, por sus siglas en inglés), también conocido tradicionalmente como síndrome de reacción farmacológica con eosinofilia y síntomas sistémicos (DRESS, por sus siglas en inglés), es una reacción multisistémica grave desencadenada por ciertos medicamentos. Típicamente, se presenta con un inicio retardado de fiebre, erupción cutánea, linfadenopatía, anomalías hematológicas y afectación de órganos sistémicos como el hígado, los riñones y los pulmones. La incidencia del DHS varía entre 1 en 1.000 y 1 en 10.000 exposiciones a medicamentos, influenciada por predisposiciones genéticas, etnicidad y factores demográficos. Los criterios diagnósticos difieren entre regiones, con los sistemas europeos (RegiSCAR), americanos y japoneses que ofrecen marcos distintos que complican la estandarización. El reconocimiento temprano y la intervención son cruciales para mejorar los resultados y reducir la mortalidad, que puede alcanzar hasta el 10%. Esta revisión explora la epidemiología, la fisiopatología, la presentación clínica, los criterios diagnósticos, las complicaciones, las estrategias de tratamiento, el pronóstico y las futuras direcciones para el DHS, enfatizando la necesidad de un enfoque diagnóstico unificado y la medicina personalizada basada en el cribado genético y los marcadores virales.
- 1 October 2026
- Published by Medipiel Servicios Administrativos in Dermatología Cosmética, Médica y Quirúrgica
- Vol. 24 (3) , 420-430
Síndrome de hipersensibilidad a medicamentos: revisión de la literatura con énfasis en los criterios diagnósticos
El síndrome de hipersensibilidad a medicamentos (DHS, por sus siglas en inglés), también conocido tradicionalmente como síndrome de reacción farmacológica con eosinofilia y síntomas sistémicos (DRESS, por sus siglas en inglés), es una reacción multisistémica grave desencadenada por ciertos medicamentos. Típicamente, se presenta con un inicio retardado de fiebre, erupción cutánea, linfadenopatía, anomalías hematológicas y afectación de órganos sistémicos como el hígado, los riñones y los pulmones. La incidencia del DHS varía entre 1 en 1.000 y 1 en 10.000 exposiciones a medicamentos, influenciada por predisposiciones genéticas, etnicidad y factores demográficos. Los criterios diagnósticos difieren entre regiones, con los sistemas europeos (RegiSCAR), americanos y japoneses que ofrecen marcos distintos que complican la estandarización. El reconocimiento temprano y la intervención son cruciales para mejorar los resultados y reducir la mortalidad, que puede alcanzar hasta el 10%. Esta revisión explora la epidemiología, la fisiopatología, la presentación clínica, los criterios diagnósticos, las complicaciones, las estrategias de tratamiento, el pronóstico y las futuras direcciones para el DHS, enfatizando la necesidad de un enfoque diagnóstico unificado y la medicina personalizada basada en el cribado genético y los marcadores virales.
- 1 October 2026
- Published by Medipiel Servicios Administrativos in Dermatología Cosmética, Médica y Quirúrgica
- Vol. 24 (3) , 456-459
La pintura que detectó primero la dermatomiositis
- 1 October 2026
- Published by Medipiel Servicios Administrativos in Dermatología Cosmética, Médica y Quirúrgica
- Vol. 24 (3) , 456-459
La pintura que detectó primero la dermatomiositis
- 1 October 2026
- Published by Medipiel Servicios Administrativos in Dermatología Cosmética, Médica y Quirúrgica
- Vol. 24 (3) , 438-451
Queratosis pilaris: una revisión
La queratosis pilaris (QP) es una dermatosis folicular benigna y altamente prevalente, caracterizada por pápulas hiperqueratósicas centradas en el folículo piloso que afectan predominantemente las superficies extensoras de brazos, muslos y glúteos. Aunque suele ser asintomática, su impacto cosmético puede generar afectación significativa en la calidad de vida, especialmente en adolescentes y adultos jóvenes. Esta revisión integra la evidencia actual sobre su epidemiología, fisiopatogenia, variantes clínicas, diagnóstico diferencial, asociaciones sistémicas y estrategias terapéuticas contemporáneas. La QP afecta hasta 40% de la población general, con inicio predominante en la infancia y adolescencia y mayor frecuencia en mujeres. Su fisiopatología involucra hiperqueratinización infundibular y disfunción de la barrera epidérmica, con asociaciones moleculares relevantes en mutaciones de FLG y ABCA12. Se reconocen múltiples variantes clínicas, incluyendo queratosis pilaris rubra, eritromelanosis follicularis faciei et colli y el espectro atrófico, cada una con implicaciones diagnósticas y terapéuticas particulares. Entre las asociaciones clínicas destacan ictiosis vulgar, alteraciones metabólicas y ciertos síndromes genéticos. El manejo debe ser individualizado y escalonado, iniciando con medidas de reparación de barrera y queratolíticos tópicos; retinoides tópicos, peelings químicos y terapias con láser o fuentes de luz constituyen opciones eficaces en casos refractarios. Los retinoides sistémicos se reservan para enfermedad extensa o de alto impacto psicosocial. En conclusión, la QP es una entidad heterogénea cuyo abordaje requiere estrategias personalizadas y mantenimiento continuo para optimizar resultados clínicos.
- 1 October 2026
- Published by Medipiel Servicios Administrativos in Dermatología Cosmética, Médica y Quirúrgica
- Vol. 24 (3) , 438-451
Queratosis pilaris: una revisión
La queratosis pilaris (QP) es una dermatosis folicular benigna y altamente prevalente, caracterizada por pápulas hiperqueratósicas centradas en el folículo piloso que afectan predominantemente las superficies extensoras de brazos, muslos y glúteos. Aunque suele ser asintomática, su impacto cosmético puede generar afectación significativa en la calidad de vida, especialmente en adolescentes y adultos jóvenes. Esta revisión integra la evidencia actual sobre su epidemiología, fisiopatogenia, variantes clínicas, diagnóstico diferencial, asociaciones sistémicas y estrategias terapéuticas contemporáneas. La QP afecta hasta 40% de la población general, con inicio predominante en la infancia y adolescencia y mayor frecuencia en mujeres. Su fisiopatología involucra hiperqueratinización infundibular y disfunción de la barrera epidérmica, con asociaciones moleculares relevantes en mutaciones de FLG y ABCA12. Se reconocen múltiples variantes clínicas, incluyendo queratosis pilaris rubra, eritromelanosis follicularis faciei et colli y el espectro atrófico, cada una con implicaciones diagnósticas y terapéuticas particulares. Entre las asociaciones clínicas destacan ictiosis vulgar, alteraciones metabólicas y ciertos síndromes genéticos. El manejo debe ser individualizado y escalonado, iniciando con medidas de reparación de barrera y queratolíticos tópicos; retinoides tópicos, peelings químicos y terapias con láser o fuentes de luz constituyen opciones eficaces en casos refractarios. Los retinoides sistémicos se reservan para enfermedad extensa o de alto impacto psicosocial. En conclusión, la QP es una entidad heterogénea cuyo abordaje requiere estrategias personalizadas y mantenimiento continuo para optimizar resultados clínicos.
- Open Access
- 11 July 2026
- Published by Wiley in JEADV Clinical Practice
Ulcus Rodens on Canvas: Cutaneous Malignancy in Ivanov's Heads of Slaves
Alexander Andreyevich Ivanov (1806–1858), a central figure of Russian academic painting, devoted more than two decades to preparatory studies for his monumental canvas The Appearance of Christ to the People . Among these works, Heads of Slaves (Figure 1) stands out for its intense physiognomic realism and ethnographic attention. Rather than idealizing his sitters, Ivanov rendered two male figures with deeply individualized features: coarse hair, sun‐weathered skin, asymmetrical facial musculature, and pronounced wrinkles. These studies were intended to capture humanity in its diversity, reflecting the artist's broader philosophical aim of portraying spiritual awakening across social strata. In this context, the painting functions not merely as an academic exercise but as a close observational record of lived bodies (1–2).
- 11 July 2026
- Published by Wiley in JEADV Clinical Practice
Open AccessUlcus Rodens on Canvas: Cutaneous Malignancy in Ivanov's Heads of Slaves
Alexander Andreyevich Ivanov (1806–1858), a central figure of Russian academic painting, devoted more than two decades to preparatory studies for his monumental canvas The Appearance of Christ to the People . Among these works, Heads of Slaves (Figure 1) stands out for its intense physiognomic realism and ethnographic attention. Rather than idealizing his sitters, Ivanov rendered two male figures with deeply individualized features: coarse hair, sun‐weathered skin, asymmetrical facial musculature, and pronounced wrinkles. These studies were intended to capture humanity in its diversity, reflecting the artist's broader philosophical aim of portraying spiritual awakening across social strata. In this context, the painting functions not merely as an academic exercise but as a close observational record of lived bodies (1–2).
- Open Access
- 25 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (2)
Insulin resistance and metabolic health predict cardiorespiratory fitness: cohort study
Aims/aims: Decreased cardiorespiratory fitness (CRF) is an all-cause mortality predictor. Oxygen consumption at peak exercise (VO2max) during a cardiopulmonary exercise test (CPET) is the gold standard for its evaluation. Since cardiometabolic risk factors reduce CRF, we aimed to assess the cardiopulmonary and metabolic responses during CPET and evaluate their determinants. Methods and results: Subjects underwent incremental treadmill CPET and bioelectrical impedance analysis. Insulin sensitivity was estimated using the HOMA, QUICKI, and METS-IR indices. Multivariate regressions were used to evaluate determinants of VO2max. Nonlinearity was confirmed with an F-test between linear and polynomial models. Five hundred and three subjects were evaluated, 474 met maximum effort criteria, (64% females). Median age was 4(26–52); 41% had normal weight, 33% overweight, 26% obesity. Prevalence of insulin resistance ranged from 22% to 46%, depending on the equation used. VO2max was 29.8(24–36) and 36.6 (30.6–43.3) mL/kg/min for females and males. Body composition analysis revealed that a higher BMI exhibited strong biological collinearity with metrics associated with adiposity excess and was inversely associated with CRF. After adjusting for age, sex, BMI, and fat mass, insulin resistance evaluated by QUICKI explained up to 43% of VO2max variability and was inversely associated with CRF. Conclusion: In a cohort of individuals without established CVD, the main determinants of CRF were modifiable risk factors associated with excess adiposity and insulin resistance. The potential mechanisms underlying the reduction in CRF include decreased relative muscle mass and insulin resistance, which reduce muscle glucose uptake and O2 consumption during maximum effort, where anaerobic glycolysis plays a central role.
- 25 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (2)
Open AccessInsulin resistance and metabolic health predict cardiorespiratory fitness: cohort study
Aims/aims: Decreased cardiorespiratory fitness (CRF) is an all-cause mortality predictor. Oxygen consumption at peak exercise (VO2max) during a cardiopulmonary exercise test (CPET) is the gold standard for its evaluation. Since cardiometabolic risk factors reduce CRF, we aimed to assess the cardiopulmonary and metabolic responses during CPET and evaluate their determinants. Methods and results: Subjects underwent incremental treadmill CPET and bioelectrical impedance analysis. Insulin sensitivity was estimated using the HOMA, QUICKI, and METS-IR indices. Multivariate regressions were used to evaluate determinants of VO2max. Nonlinearity was confirmed with an F-test between linear and polynomial models. Five hundred and three subjects were evaluated, 474 met maximum effort criteria, (64% females). Median age was 4(26–52); 41% had normal weight, 33% overweight, 26% obesity. Prevalence of insulin resistance ranged from 22% to 46%, depending on the equation used. VO2max was 29.8(24–36) and 36.6 (30.6–43.3) mL/kg/min for females and males. Body composition analysis revealed that a higher BMI exhibited strong biological collinearity with metrics associated with adiposity excess and was inversely associated with CRF. After adjusting for age, sex, BMI, and fat mass, insulin resistance evaluated by QUICKI explained up to 43% of VO2max variability and was inversely associated with CRF. Conclusion: In a cohort of individuals without established CVD, the main determinants of CRF were modifiable risk factors associated with excess adiposity and insulin resistance. The potential mechanisms underlying the reduction in CRF include decreased relative muscle mass and insulin resistance, which reduce muscle glucose uptake and O2 consumption during maximum effort, where anaerobic glycolysis plays a central role.
- 27 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (6) , 944-945
Ink, identity and the Belle Époque: Interpreting the tattoo in Toulouse‐Lautrec's La Femme Tatouée
- 27 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (6) , 944-945
Ink, identity and the Belle Époque: Interpreting the tattoo in Toulouse‐Lautrec's La Femme Tatouée
- 26 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (4) , 574-575
From canvas to clinic: Atopic clues in Van Gogh's Boy with an Orange
- 26 November 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (4) , 574-575
From canvas to clinic: Atopic clues in Van Gogh's Boy with an Orange
- Open Access
- 26 May 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 1-12
Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution
Approximately 20% of the global population has a Lp(a) concentrations above 50 mg/dL (> 125nmol/L), yet many remain unaware of the associated cardiovascular risks. In Mexico, routine measurement of Lp(a) is uncommon. This study aimed to investigate the frequency of Lp(a) testing, and the clinical actions taken by physicians upon detecting elevated Lp(a) concentrations in patients at a tertiary medical institution. Using an algorithm-based screening system, we reviewed the clinical and biochemical data of patients with Lp(a) measurements from 2019 to 2024. Data were retrieved from the laboratory information system and electronic health records. Complementary assessment data were obtained from the radiology and cardiology departments. Of the 150,083 individuals evaluated at the institution, only 830 (0.5%) underwent Lp(a) testing, with testing rates increasing from 0.037% in 2019 to 0.24% in 2023. Elevated Lp(a) concentrations (> 50 mg/dL) were found in 21% of patients, and 2.2% had concentrations > 180 mg/dL. Patients with elevated Lp(a) had significantly higher rates of atherosclerotic cardiovascular disease (ASCVD) (p < 0.001) and familial hypercholesterolemia (p < 0.004) than those with lower Lp(a) levels. Interestingly, diabetes prevalence was higher in those with Lp(a) < 4 mg/dL (51.5% vs. 33.4%, p < 0.001). Despite the cardiovascular risk, only 26% of patients with elevated Lp(a) levels received interventions to modify risk factors. Lp(a) testing was infrequent in a tertiary medical setting. Clinical interventions to modify cardiovascular risk factors were insufficient among patients with elevated Lp(a). These findings highlight the need for greater awareness among healthcare providers and the development of comprehensive screening and management algorithms to mitigate Lp(a) -related cardiovascular risk.
- 26 May 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 1-12
Open AccessLipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution
Approximately 20% of the global population has a Lp(a) concentrations above 50 mg/dL (> 125nmol/L), yet many remain unaware of the associated cardiovascular risks. In Mexico, routine measurement of Lp(a) is uncommon. This study aimed to investigate the frequency of Lp(a) testing, and the clinical actions taken by physicians upon detecting elevated Lp(a) concentrations in patients at a tertiary medical institution. Using an algorithm-based screening system, we reviewed the clinical and biochemical data of patients with Lp(a) measurements from 2019 to 2024. Data were retrieved from the laboratory information system and electronic health records. Complementary assessment data were obtained from the radiology and cardiology departments. Of the 150,083 individuals evaluated at the institution, only 830 (0.5%) underwent Lp(a) testing, with testing rates increasing from 0.037% in 2019 to 0.24% in 2023. Elevated Lp(a) concentrations (> 50 mg/dL) were found in 21% of patients, and 2.2% had concentrations > 180 mg/dL. Patients with elevated Lp(a) had significantly higher rates of atherosclerotic cardiovascular disease (ASCVD) (p < 0.001) and familial hypercholesterolemia (p < 0.004) than those with lower Lp(a) levels. Interestingly, diabetes prevalence was higher in those with Lp(a) < 4 mg/dL (51.5% vs. 33.4%, p < 0.001). Despite the cardiovascular risk, only 26% of patients with elevated Lp(a) levels received interventions to modify risk factors. Lp(a) testing was infrequent in a tertiary medical setting. Clinical interventions to modify cardiovascular risk factors were insufficient among patients with elevated Lp(a). These findings highlight the need for greater awareness among healthcare providers and the development of comprehensive screening and management algorithms to mitigate Lp(a) -related cardiovascular risk.